Home » Advisory Panel Votes Against Recommending BMS, AZ Diabetes Drug
Advisory Panel Votes Against Recommending BMS, AZ Diabetes Drug
An FDA panel voted 9-6 against recommending approval of Bristol-Myers Squibb (BMS) and AstraZeneca’s diabetes drug dapagliflozin, citing cancer risks and a lack of substantial evidence.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May